Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation

ENG / FRA / DEU

Gene Signal announces publication of positive results from Phase IIa study of topical aganirsen in psoriasis

ENG / FRA

Gene Signal announces completion of private funding round

Company set to embark on aggressive three-year clinical and commercialisation plan for angiogenesis therapies

ENG / FRA / DEU

Gene Signal Presents Positive Data at ARVO 2012 Demonstrating Topical Aganirsen is Active in Models of Retinal Neovascular disease 

ENG

Topical Aganirsen Shows Efficacy in AMD and Ischemic Retinopathy Models 

ENG

Expert Ophthalmology Panel Releases Consensus Statement on the Management of Corneal Diseases associated with Neovascularisation

ENG / DEU

Results of a Meta-Analysis Show Neovascularization Increases Risk for Corneal Transplant Rejection and Failure

ENG / FRA

Gene Signal and Collaborators Publish GS-101 Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth

ENG / FRA / DEU / ESP /

Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 for Diseases of the Eye

ENG

Gene Signal enters Phase III Clinical Tests for the prevention of Corneal Graft Rejection

ENG / FRA / DEU